1 / 11

Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan

Update in ESC: Dabigatran among OAC. Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan Professor, Ken Okumura. Age 81 Female (Living alone, ADL: independent ) Chronic AF HT(-), No heart disease, DM(-), LAD 43mm. dementia. nose bleed. dementia. dementia.

earl
Télécharger la présentation

Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update in ESC: Dabigatran among OAC Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan Professor, Ken Okumura

  2. Age 81 Female (Living alone, ADL: independent ) Chronic AFHT(-), No heart disease, DM(-), LAD 43mm dementia nose bleed dementia dementia Stroke Warfarin(2002~) 2.5mg 2.5mg aspirin 2.5mg 1.5mg 4 3.53 3 2.16 2.15 2.1 2.13 PT-INR 2 1.35 1.54 1.16 1.36 1 0.91 0.87 0.81 0.81 0.78 0 2004 Jan 2005 Jan Feb Mar Apr May Oct Nov Dec Feb Mar Apr

  3. Age 81 Female(Living alone, ADL: independent ) Chronic AFHT(-), No heart disease, DM(-), LAD 43mm 29th 4,2005 14th 5,2005

  4. mRS by subtype of brain infaction(HIROSAKI Stroke and Rehabilitation Center) n=768 (Oct, 2005~Jan, 2008) m-Rankin scale No symptoms 0 Lacunar (n=215) Able to carry out all usual activities 1 Able to look after own affairs without assistance 2 Atherothrombotic infarction (n=308) Requires some help, but able to walk unassisted 3 Unable to walk unassisted 4 31% 54% Cerebral embolism (n=245) Bedridden 5 Dead 6 0 20 40 60 80 100 (%) Ken Okumura, Norihumi Metoki, Jyoji HagiiJapanese Journal of Electrocardiology2011;31:292-296

  5. Prevalence of AF among Cerebral embolism patients: 267 consecutive patients during 2008-2009 (HIROSAKI Stroke and Rehabilitation Center) Data from previous Dr & ECG during hospitalization ECG on admission AF(-) n=67 (25%) AF(-) n=128 (48%) AF(+) n=139 (52%) Sustained AF n=120 (45%) paroxysmal AF n=80 (30%) Ken Okumura, Norihumi Metoki, Jyoji HagiiJapanese Journal of Electrocardiology2011;31:292-296

  6. Severity of stroke by AF type Sustained AF vsParoxysmal AF vsNot defined AF (HIROSAKI Stroke and Rehabilitation Center) Percentage of patients with mRS = 4,5,6 (P＝NS) Percentage ofpatients with internal carotid artery stenosis (P＝NS) Sustained (n=120) 23 97 57 63 Paroxysmal (n=80) 12 68 33 47 Not defined AF (n=67) 9 58 25 42 0 20 40 60 80 100 (%) 0 20 40 60 80 100 (%) *Patients with acute stroke within 3 hours of onset were treated with tPA

  7. CHADS2 Score and Severity of stroke CHADS2=0,1 Score (n=41)vs CHADS2=2-6 Score(n=159) (HIROSAKI Stroke and Rehabilitation Center) Percentage of patients with mRS = 4,5,6 (P＝NS) Percentage ofpatients with internal carotid artery stenosis (P＝NS) CHADS2=0,1 (n=41) 9 32 17 24 CHADS2=2-6 (n=159) 34 125 73 86 0 20 40 60 80 100 (%) 0 20 40 60 80 100 (%)

  8. The Japanese Society of Electrocardiology J-RHYTHM Registry CHADS2 Score of registered AF patients (n=7,937) J-RHYTHM Registry J-RHYTHM Registry (%) 35 30 (cases) 100 25 80 18.2% 20 Incidence for stroke National Registry of AF 60 15 12.5% 40 8.5% 10 5.9% 4.0% 20 5 2.8% 1.9% 0 0 0 1 2 3 4 5 6 CHADS2 Score

  9. Net Clinical Benefit in ATRIA Study (Singer DE, et al. Ann Intern Med 2009;151:297-305) 13,559 adults with non-valvular atrial fibrillation at Kaiser Permanente Northern California (73 years median age; Male 57%; more than 66,000 person-years of observation; 53% of patients were receiving warfarin treatment.) → 1,092 thromboembolic events, 299 intracranial hemorrhagic events 2.22 4-6 0.58 3.75 2.07 3 1.21 2.79 0.97 CHADS2 score 2 0.43 1.41 0.19 Net clinical benefit of warfarin =0.68%/yr Net clinical benefit of patients with Prior Stroke =2.48%/yr 1 -0.27 0.45 -0.11 0 -0.44 0.20 -1 -0.5 0 0.5 1 1.5 2 2.5 3 3.5 Worse with Warfarin Better with Warfarin Net Clinical Benefit ＝(TE rate off warfarin −TE rate on warfarin) − 1.5 x (ICH rate on warfarin −ICH rateoff warfarin)

  10. Intracranial hemorrhage rate Intracranial hemorrhage: Hemorrhagic Stroke (Intracerebral hemorrhage), Subdural hematoma and Subarachnoid hemorrhage RR 0.41 (95%CI: 0.28–0.60) P<0.001 RR 0.30 (95%CI: 0.19–0.45) P<0.001 1.0 Event rate (% per year) 0.8 0.76 0.6 RRR 59% 0.4 RRR 70% 0.32 0.2 0.23 0 Dabigatran 150mg bid (n=38/6,076) Dabigatran 110mg bid (n=27/6,015) Warfarin (n=90/6,022) Connolly SJ, et al: N Engl J Med 361, 1139-1151, 2009 Connolly SJ, et al: N Engl J Med 363, 1875-1876, 2010

  11. Urgent Statement on Antithrombotic Therapy of Atrial Fibrillation : JCS Guideline Statement (Aug.2011) Mitral stenosis or mechanical valve Non-valvular AF Other risk factors Cardiomyopathy 65 to 74 years old Female patients Coronary heart disease Thyrotoxicosis CHADS2Score Heart failure 1point Hypertension 1point ≥75years old 1point Diabetes 1point History of cerebral infarction or TIA 2points ≥2points 1point Recommended Recommended Considered Considered Warfarin INR2.0to 3.0 for < 70 years old INR1.6to 2.6 for ≥ 70 years old Warfarin INR2.0to 3.0 for < 70 years old INR1.6to 2.6 for ≥ 70 years old Warfarin INR2.0to 3.0 for < 70 years old INR1.6to 2.6 for ≥ 70 years old Warfarin INR2.0~3.0 Dabigatran Recommended Dabigatran Dabigatran JCS: Urgent Statement 2011http://www.j-circ.or.jp/guideline/pdf/statement.pdf

More Related